In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

Data on Pfizer-BioNTech in 5-12 year olds (Pfizer)
Safety of additional vaccine dose (MMWR)
Oklahoma reinfection rates (OK DOH)
Regencov outcomes (NEJM)
Pfizer protease inhibitor trial (Pfizer)
WHO recommends antibody therapy (Hosp Health)
Tocilizumab use in hospitalized patients (Resp Care)
Long COVID (PLoS Medicine)
Letters read on TWiV 811
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

TWiV 811: COVID-19 clinical update #82 with Dr. Daniel Griffin